For non-ST elevation acute coronary syndrome (NSTE-ACS). ANDA 213947, held by Nexus. Tirofiban Hydrochloride.
As of Nov 16, 2026, ANDA 213947 (Tirofiban Hydrochloride), held by Nexus, was first approved by FDA on Jul 24, 2023, with 0 approved supplements and 0 published complete response letters.
Tirofiban Hydrochloride Injection is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
| Jul 24, 2023 | Original application | Approved | None posted |
| Feb 7, 2023 | Original application | Approved |
| Tirofiban HydrochlorideEQ 5MG BASE/100ML (EQ 0.05MG BASE/ML) · solution;intravenous | Tirofiban Hydrochloride | Rx |
| Tirofiban HydrochlorideEQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML) · solution;intravenous | Tirofiban Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters